Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
reducing cardiac output
is a activin receptor-like kinase-2 (ALK2) inhibitor extracted from patent WO2017181117A1
Salinomycin
selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1)
IWR-1-endo
Fluvastatin Sodium thoxyisoflavone reducing cardiac outputFluvastatin sodium is an HMG CoA reductase inhibitor used to lower cholesterol and lipid levels. It may inhibit RhoA. It also prevents viral replication of hepatitis C, decreases platelet activation, scavenges hydroxyl radicals, induces cell cycle arrest and apoptosis in hepatocellular carcinoma cells, and improves left ventricular function and prevents fibrosis in cardiac distress models. Product information CAS Number: 93957 55 2 Molecular Weight:
US$ 105.00
US$ 175.00
US$ 200.00
US$ 35.00
US$ 58.00
US$ 42.00
US$ 58.00
US$ 130.00
US$ 165.00
US$ 112.50
US$ 45.00
US$ 55.00
US$ 720.00
US$ 10.00
US$ 150.00
US$ 83.09